Justice Angela

SEC source: 0001104659-23-067051 · tm2317472-4_4seq1.xml · derivative · entry 7

Justice Angela · CIK 0001732986 · Chief People Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,336 shares

Expires not disclosed

F4 · derivative.exercise_price: Immediately prior to the Effective Time, each award of restricted stock unit with respect to Shares (each, a "Restricted Stock Unit"), other than Restricted Stock Units that immediately vest upon a change of control of the Company, were assumed and substituted for a restricted stock unit-style option to purchase Parent Ordinary Shares or Parent ADS, with an exercise price per Parent Ordinary Shares or Parent ADS, as applicable, equal to Pound Sterling 0.001 per Parent Ordinary Share or Pound Sterling 0.006 per Parent ADS (each, an "Adjusted Restricted Stock Unit Equivalent"), granted under one of Parent's incentive equity plans.

F5 · derivative.exercise_price: The number of Parent Ordinary Shares or Parent ADSs subject to the Adjusted Restricted Stock Unit Equivalent shall be equal to the product of (i) the total number of Shares subject to such Restricted Stock Unit immediately prior to the Effective Time multiplied by (ii) the Ordinary Share Exchange Ratio (as defined in the Merger Agreement) or the Exchange Ratio, as applicable.

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time").

F4 · kind: Immediately prior to the Effective Time, each award of restricted stock unit with respect to Shares (each, a "Restricted Stock Unit"), other than Restricted Stock Units that immediately vest upon a change of control of the Company, were assumed and substituted for a restricted stock unit-style option to purchase Parent Ordinary Shares or Parent ADS, with an exercise price per Parent Ordinary Shares or Parent ADS, as applicable, equal to Pound Sterling 0.001 per Parent Ordinary Share or Pound Sterling 0.006 per Parent ADS (each, an "Adjusted Restricted Stock Unit Equivalent"), granted under one of Parent's incentive equity plans.

F5 · kind: The number of Parent Ordinary Shares or Parent ADSs subject to the Adjusted Restricted Stock Unit Equivalent shall be equal to the product of (i) the total number of Shares subject to such Restricted Stock Unit immediately prior to the Effective Time multiplied by (ii) the Ordinary Share Exchange Ratio (as defined in the Merger Agreement) or the Exchange Ratio, as applicable.

F4 · derivative.exercise_date: Immediately prior to the Effective Time, each award of restricted stock unit with respect to Shares (each, a "Restricted Stock Unit"), other than Restricted Stock Units that immediately vest upon a change of control of the Company, were assumed and substituted for a restricted stock unit-style option to purchase Parent Ordinary Shares or Parent ADS, with an exercise price per Parent Ordinary Shares or Parent ADS, as applicable, equal to Pound Sterling 0.001 per Parent Ordinary Share or Pound Sterling 0.006 per Parent ADS (each, an "Adjusted Restricted Stock Unit Equivalent"), granted under one of Parent's incentive equity plans.

F5 · derivative.exercise_date: The number of Parent Ordinary Shares or Parent ADSs subject to the Adjusted Restricted Stock Unit Equivalent shall be equal to the product of (i) the total number of Shares subject to such Restricted Stock Unit immediately prior to the Effective Time multiplied by (ii) the Ordinary Share Exchange Ratio (as defined in the Merger Agreement) or the Exchange Ratio, as applicable.

F4 · derivative.expiration_date: Immediately prior to the Effective Time, each award of restricted stock unit with respect to Shares (each, a "Restricted Stock Unit"), other than Restricted Stock Units that immediately vest upon a change of control of the Company, were assumed and substituted for a restricted stock unit-style option to purchase Parent Ordinary Shares or Parent ADS, with an exercise price per Parent Ordinary Shares or Parent ADS, as applicable, equal to Pound Sterling 0.001 per Parent Ordinary Share or Pound Sterling 0.006 per Parent ADS (each, an "Adjusted Restricted Stock Unit Equivalent"), granted under one of Parent's incentive equity plans.

F5 · derivative.expiration_date: The number of Parent Ordinary Shares or Parent ADSs subject to the Adjusted Restricted Stock Unit Equivalent shall be equal to the product of (i) the total number of Shares subject to such Restricted Stock Unit immediately prior to the Effective Time multiplied by (ii) the Ordinary Share Exchange Ratio (as defined in the Merger Agreement) or the Exchange Ratio, as applicable.

SEC source: 0001104659-23-067051 · tm2317472-4_4seq1.xml · derivative · entry 6

Justice Angela · CIK 0001732986 · Chief People Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,050 shares

Expires not disclosed

F4 · derivative.exercise_price: Immediately prior to the Effective Time, each award of restricted stock unit with respect to Shares (each, a "Restricted Stock Unit"), other than Restricted Stock Units that immediately vest upon a change of control of the Company, were assumed and substituted for a restricted stock unit-style option to purchase Parent Ordinary Shares or Parent ADS, with an exercise price per Parent Ordinary Shares or Parent ADS, as applicable, equal to Pound Sterling 0.001 per Parent Ordinary Share or Pound Sterling 0.006 per Parent ADS (each, an "Adjusted Restricted Stock Unit Equivalent"), granted under one of Parent's incentive equity plans.

F5 · derivative.exercise_price: The number of Parent Ordinary Shares or Parent ADSs subject to the Adjusted Restricted Stock Unit Equivalent shall be equal to the product of (i) the total number of Shares subject to such Restricted Stock Unit immediately prior to the Effective Time multiplied by (ii) the Ordinary Share Exchange Ratio (as defined in the Merger Agreement) or the Exchange Ratio, as applicable.

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time").

F4 · kind: Immediately prior to the Effective Time, each award of restricted stock unit with respect to Shares (each, a "Restricted Stock Unit"), other than Restricted Stock Units that immediately vest upon a change of control of the Company, were assumed and substituted for a restricted stock unit-style option to purchase Parent Ordinary Shares or Parent ADS, with an exercise price per Parent Ordinary Shares or Parent ADS, as applicable, equal to Pound Sterling 0.001 per Parent Ordinary Share or Pound Sterling 0.006 per Parent ADS (each, an "Adjusted Restricted Stock Unit Equivalent"), granted under one of Parent's incentive equity plans.

F5 · kind: The number of Parent Ordinary Shares or Parent ADSs subject to the Adjusted Restricted Stock Unit Equivalent shall be equal to the product of (i) the total number of Shares subject to such Restricted Stock Unit immediately prior to the Effective Time multiplied by (ii) the Ordinary Share Exchange Ratio (as defined in the Merger Agreement) or the Exchange Ratio, as applicable.

F4 · derivative.exercise_date: Immediately prior to the Effective Time, each award of restricted stock unit with respect to Shares (each, a "Restricted Stock Unit"), other than Restricted Stock Units that immediately vest upon a change of control of the Company, were assumed and substituted for a restricted stock unit-style option to purchase Parent Ordinary Shares or Parent ADS, with an exercise price per Parent Ordinary Shares or Parent ADS, as applicable, equal to Pound Sterling 0.001 per Parent Ordinary Share or Pound Sterling 0.006 per Parent ADS (each, an "Adjusted Restricted Stock Unit Equivalent"), granted under one of Parent's incentive equity plans.

F5 · derivative.exercise_date: The number of Parent Ordinary Shares or Parent ADSs subject to the Adjusted Restricted Stock Unit Equivalent shall be equal to the product of (i) the total number of Shares subject to such Restricted Stock Unit immediately prior to the Effective Time multiplied by (ii) the Ordinary Share Exchange Ratio (as defined in the Merger Agreement) or the Exchange Ratio, as applicable.

F4 · derivative.expiration_date: Immediately prior to the Effective Time, each award of restricted stock unit with respect to Shares (each, a "Restricted Stock Unit"), other than Restricted Stock Units that immediately vest upon a change of control of the Company, were assumed and substituted for a restricted stock unit-style option to purchase Parent Ordinary Shares or Parent ADS, with an exercise price per Parent Ordinary Shares or Parent ADS, as applicable, equal to Pound Sterling 0.001 per Parent Ordinary Share or Pound Sterling 0.006 per Parent ADS (each, an "Adjusted Restricted Stock Unit Equivalent"), granted under one of Parent's incentive equity plans.

F5 · derivative.expiration_date: The number of Parent Ordinary Shares or Parent ADSs subject to the Adjusted Restricted Stock Unit Equivalent shall be equal to the product of (i) the total number of Shares subject to such Restricted Stock Unit immediately prior to the Effective Time multiplied by (ii) the Ordinary Share Exchange Ratio (as defined in the Merger Agreement) or the Exchange Ratio, as applicable.

SEC source: 0001104659-23-067051 · tm2317472-4_4seq1.xml · derivative · entry 5

Justice Angela · CIK 0001732986 · Chief People Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,527 shares

Expires not disclosed

F4 · derivative.exercise_price: Immediately prior to the Effective Time, each award of restricted stock unit with respect to Shares (each, a "Restricted Stock Unit"), other than Restricted Stock Units that immediately vest upon a change of control of the Company, were assumed and substituted for a restricted stock unit-style option to purchase Parent Ordinary Shares or Parent ADS, with an exercise price per Parent Ordinary Shares or Parent ADS, as applicable, equal to Pound Sterling 0.001 per Parent Ordinary Share or Pound Sterling 0.006 per Parent ADS (each, an "Adjusted Restricted Stock Unit Equivalent"), granted under one of Parent's incentive equity plans.

F5 · derivative.exercise_price: The number of Parent Ordinary Shares or Parent ADSs subject to the Adjusted Restricted Stock Unit Equivalent shall be equal to the product of (i) the total number of Shares subject to such Restricted Stock Unit immediately prior to the Effective Time multiplied by (ii) the Ordinary Share Exchange Ratio (as defined in the Merger Agreement) or the Exchange Ratio, as applicable.

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time").

F4 · kind: Immediately prior to the Effective Time, each award of restricted stock unit with respect to Shares (each, a "Restricted Stock Unit"), other than Restricted Stock Units that immediately vest upon a change of control of the Company, were assumed and substituted for a restricted stock unit-style option to purchase Parent Ordinary Shares or Parent ADS, with an exercise price per Parent Ordinary Shares or Parent ADS, as applicable, equal to Pound Sterling 0.001 per Parent Ordinary Share or Pound Sterling 0.006 per Parent ADS (each, an "Adjusted Restricted Stock Unit Equivalent"), granted under one of Parent's incentive equity plans.

F5 · kind: The number of Parent Ordinary Shares or Parent ADSs subject to the Adjusted Restricted Stock Unit Equivalent shall be equal to the product of (i) the total number of Shares subject to such Restricted Stock Unit immediately prior to the Effective Time multiplied by (ii) the Ordinary Share Exchange Ratio (as defined in the Merger Agreement) or the Exchange Ratio, as applicable.

F4 · derivative.exercise_date: Immediately prior to the Effective Time, each award of restricted stock unit with respect to Shares (each, a "Restricted Stock Unit"), other than Restricted Stock Units that immediately vest upon a change of control of the Company, were assumed and substituted for a restricted stock unit-style option to purchase Parent Ordinary Shares or Parent ADS, with an exercise price per Parent Ordinary Shares or Parent ADS, as applicable, equal to Pound Sterling 0.001 per Parent Ordinary Share or Pound Sterling 0.006 per Parent ADS (each, an "Adjusted Restricted Stock Unit Equivalent"), granted under one of Parent's incentive equity plans.

F5 · derivative.exercise_date: The number of Parent Ordinary Shares or Parent ADSs subject to the Adjusted Restricted Stock Unit Equivalent shall be equal to the product of (i) the total number of Shares subject to such Restricted Stock Unit immediately prior to the Effective Time multiplied by (ii) the Ordinary Share Exchange Ratio (as defined in the Merger Agreement) or the Exchange Ratio, as applicable.

F4 · derivative.expiration_date: Immediately prior to the Effective Time, each award of restricted stock unit with respect to Shares (each, a "Restricted Stock Unit"), other than Restricted Stock Units that immediately vest upon a change of control of the Company, were assumed and substituted for a restricted stock unit-style option to purchase Parent Ordinary Shares or Parent ADS, with an exercise price per Parent Ordinary Shares or Parent ADS, as applicable, equal to Pound Sterling 0.001 per Parent Ordinary Share or Pound Sterling 0.006 per Parent ADS (each, an "Adjusted Restricted Stock Unit Equivalent"), granted under one of Parent's incentive equity plans.

F5 · derivative.expiration_date: The number of Parent Ordinary Shares or Parent ADSs subject to the Adjusted Restricted Stock Unit Equivalent shall be equal to the product of (i) the total number of Shares subject to such Restricted Stock Unit immediately prior to the Effective Time multiplied by (ii) the Ordinary Share Exchange Ratio (as defined in the Merger Agreement) or the Exchange Ratio, as applicable.

SEC source: 0001104659-23-067051 · tm2317472-4_4seq1.xml · derivative · entry 4

Justice Angela · CIK 0001732986 · Chief People Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,083 shares

Expires not disclosed

F4 · derivative.exercise_price: Immediately prior to the Effective Time, each award of restricted stock unit with respect to Shares (each, a "Restricted Stock Unit"), other than Restricted Stock Units that immediately vest upon a change of control of the Company, were assumed and substituted for a restricted stock unit-style option to purchase Parent Ordinary Shares or Parent ADS, with an exercise price per Parent Ordinary Shares or Parent ADS, as applicable, equal to Pound Sterling 0.001 per Parent Ordinary Share or Pound Sterling 0.006 per Parent ADS (each, an "Adjusted Restricted Stock Unit Equivalent"), granted under one of Parent's incentive equity plans.

F5 · derivative.exercise_price: The number of Parent Ordinary Shares or Parent ADSs subject to the Adjusted Restricted Stock Unit Equivalent shall be equal to the product of (i) the total number of Shares subject to such Restricted Stock Unit immediately prior to the Effective Time multiplied by (ii) the Ordinary Share Exchange Ratio (as defined in the Merger Agreement) or the Exchange Ratio, as applicable.

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time").

F4 · kind: Immediately prior to the Effective Time, each award of restricted stock unit with respect to Shares (each, a "Restricted Stock Unit"), other than Restricted Stock Units that immediately vest upon a change of control of the Company, were assumed and substituted for a restricted stock unit-style option to purchase Parent Ordinary Shares or Parent ADS, with an exercise price per Parent Ordinary Shares or Parent ADS, as applicable, equal to Pound Sterling 0.001 per Parent Ordinary Share or Pound Sterling 0.006 per Parent ADS (each, an "Adjusted Restricted Stock Unit Equivalent"), granted under one of Parent's incentive equity plans.

F5 · kind: The number of Parent Ordinary Shares or Parent ADSs subject to the Adjusted Restricted Stock Unit Equivalent shall be equal to the product of (i) the total number of Shares subject to such Restricted Stock Unit immediately prior to the Effective Time multiplied by (ii) the Ordinary Share Exchange Ratio (as defined in the Merger Agreement) or the Exchange Ratio, as applicable.

F4 · derivative.exercise_date: Immediately prior to the Effective Time, each award of restricted stock unit with respect to Shares (each, a "Restricted Stock Unit"), other than Restricted Stock Units that immediately vest upon a change of control of the Company, were assumed and substituted for a restricted stock unit-style option to purchase Parent Ordinary Shares or Parent ADS, with an exercise price per Parent Ordinary Shares or Parent ADS, as applicable, equal to Pound Sterling 0.001 per Parent Ordinary Share or Pound Sterling 0.006 per Parent ADS (each, an "Adjusted Restricted Stock Unit Equivalent"), granted under one of Parent's incentive equity plans.

F5 · derivative.exercise_date: The number of Parent Ordinary Shares or Parent ADSs subject to the Adjusted Restricted Stock Unit Equivalent shall be equal to the product of (i) the total number of Shares subject to such Restricted Stock Unit immediately prior to the Effective Time multiplied by (ii) the Ordinary Share Exchange Ratio (as defined in the Merger Agreement) or the Exchange Ratio, as applicable.

F4 · derivative.expiration_date: Immediately prior to the Effective Time, each award of restricted stock unit with respect to Shares (each, a "Restricted Stock Unit"), other than Restricted Stock Units that immediately vest upon a change of control of the Company, were assumed and substituted for a restricted stock unit-style option to purchase Parent Ordinary Shares or Parent ADS, with an exercise price per Parent Ordinary Shares or Parent ADS, as applicable, equal to Pound Sterling 0.001 per Parent Ordinary Share or Pound Sterling 0.006 per Parent ADS (each, an "Adjusted Restricted Stock Unit Equivalent"), granted under one of Parent's incentive equity plans.

F5 · derivative.expiration_date: The number of Parent Ordinary Shares or Parent ADSs subject to the Adjusted Restricted Stock Unit Equivalent shall be equal to the product of (i) the total number of Shares subject to such Restricted Stock Unit immediately prior to the Effective Time multiplied by (ii) the Ordinary Share Exchange Ratio (as defined in the Merger Agreement) or the Exchange Ratio, as applicable.

SEC source: 0001104659-23-067051 · tm2317472-4_4seq1.xml · derivative · entry 3

Justice Angela · CIK 0001732986 · Chief People Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 76,500 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time").

F3 · kind: Immediately prior to the Effective Time, each option to acquire Shares (each, a "Company Option") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs.

F3 · derivative.exercise_date: Immediately prior to the Effective Time, each option to acquire Shares (each, a "Company Option") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs.

F3 · derivative.expiration_date: Immediately prior to the Effective Time, each option to acquire Shares (each, a "Company Option") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs.

SEC source: 0001104659-23-067051 · tm2317472-4_4seq1.xml · derivative · entry 2

Justice Angela · CIK 0001732986 · Chief People Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 78,499 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time").

F3 · kind: Immediately prior to the Effective Time, each option to acquire Shares (each, a "Company Option") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs.

F3 · derivative.exercise_date: Immediately prior to the Effective Time, each option to acquire Shares (each, a "Company Option") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs.

F3 · derivative.expiration_date: Immediately prior to the Effective Time, each option to acquire Shares (each, a "Company Option") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs.

SEC source: 0001104659-23-067051 · tm2317472-4_4seq1.xml · nonDerivative · entry 1

Justice Angela · CIK 0001732986 · Chief People Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time").

F2 · price: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares").

SEC source: 0000899243-22-039026 · doc4.xml · derivative · entry 3

Justice Angela · CIK 0001732986 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,083

Underlying: Common Stock · 13,083 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a right to receive one share of the issuer's common stock at the time of vesting for no consideration.

F3 · derivative.exercise_date: The restricted stock units will vest 25% on the one-year anniversary of the date of grant, with the remainder vesting in three equal annual installments thereafter.

F3 · derivative.expiration_date: The restricted stock units will vest 25% on the one-year anniversary of the date of grant, with the remainder vesting in three equal annual installments thereafter.

SEC source: 0000899243-22-039026 · doc4.xml · derivative · entry 2

Justice Angela · CIK 0001732986 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,499

Underlying: Common Stock · 78,499 shares

Expires 2032-12-14

F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on the one-year anniversary of the date of grant, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.

SEC source: 0000899243-22-038381 · doc4.xml · nonDerivative · entry 4

Justice Angela · CIK 0001732986 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,745

F1 · kind: The sales reported represent the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1.

SEC source: 0000899243-22-038381 · doc4.xml · nonDerivative · entry 3

Justice Angela · CIK 0001732986 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,708

F1 · kind: The sales reported represent the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1.

SEC source: 0000899243-22-038381 · doc4.xml · nonDerivative · entry 2

Justice Angela · CIK 0001732986 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,573

F1 · kind: The sales reported represent the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1.

SEC source: 0000899243-22-038097 · doc4.xml · nonDerivative · entry 3

Justice Angela · CIK 0001732986 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,365

F1 · kind: The sales reported represent the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1.

SEC source: 0000899243-22-038097 · doc4.xml · nonDerivative · entry 2

Justice Angela · CIK 0001732986 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,876

F1 · kind: The sales reported represent the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1.

SEC source: 0000899243-22-037940 · doc4.xml · nonDerivative · entry 3

Justice Angela · CIK 0001732986 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,333

F1 · kind: The sales reported represent the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1.

SEC source: 0000899243-22-037940 · doc4.xml · nonDerivative · entry 2

Justice Angela · CIK 0001732986 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,694

F1 · kind: The sales reported represent the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1.

SEC source: 0001209191-22-059880 · doc4.xml · nonDerivative · entry 3

Justice Angela · CIK 0001732986 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,996

F3 · kind: The sales reported represent the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1.

SEC source: 0001209191-22-059880 · doc4.xml · derivative · entry 6

Justice Angela · CIK 0001732986 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,336

Underlying: Common Stock · 5,847 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a right to receive one share of the issuer's common stock at the time of vesting for no consideration.

F6 · derivative.exercise_date: 48% of these restricted stock units vested on December 1, 2022, 25% will vest on December 1, 2023, 25% will vest on December 1, 2024 and the remaining 2% will vest on December 1, 2025.

F6 · derivative.expiration_date: 48% of these restricted stock units vested on December 1, 2022, 25% will vest on December 1, 2023, 25% will vest on December 1, 2024 and the remaining 2% will vest on December 1, 2025.

SEC source: 0001209191-22-059880 · doc4.xml · derivative · entry 5

Justice Angela · CIK 0001732986 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,050

Underlying: Common Stock · 2,840 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a right to receive one share of the issuer's common stock at the time of vesting for no consideration.

F5 · derivative.exercise_date: 73% of these restricted stock units vested on December 1, 2022, 25% will vest on December 1, 2023 and the remaining 2% will vest on December 1, 2024.

F5 · derivative.expiration_date: 73% of these restricted stock units vested on December 1, 2022, 25% will vest on December 1, 2023 and the remaining 2% will vest on December 1, 2024.

SEC source: 0001209191-22-059880 · doc4.xml · derivative · entry 4

Justice Angela · CIK 0001732986 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,527

Underlying: Common Stock · 50,889 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a right to receive one share of the issuer's common stock at the time of vesting for no consideration.

F4 · derivative.exercise_date: 79% of these restricted stock units vested on December 1, 2022 and the remaining 21% will vest on December 1, 2023.

F4 · derivative.expiration_date: 79% of these restricted stock units vested on December 1, 2022 and the remaining 21% will vest on December 1, 2023.

SEC source: 0001209191-22-059880 · doc4.xml · nonDerivative · entry 2

Justice Angela · CIK 0001732986 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,269

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the the aggregate number of common stock converted from restricted stock units granted to the reporting person on 11/17/2022 pursuant to the issuer's offer to exchange eligible options for new restricted stock units program.

F2 · price: Each restricted stock unit represents a right to receive one share of the issuer's common stock at the time of vesting for no consideration.

SEC source: 0000899243-22-036383 · doc4.xml · derivative · entry 13

Justice Angela · CIK 0001732986 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,380

Underlying: Common Stock · 11,380 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents a right to receive one share of the issuer's common stock at the time of vesting for no consideration.

F13 · price: On November 17, 2022, the issuer cancelled, pursuant to the issuer's offer to exchange eligible options for new restricted stock units program, a stock option granted to the reporting person on December 10, 2020. In exchange for such stock option, the reporting person received restricted stock units in the amount of 11,380.

F12 · derivative.exercise_date: 48% of these restricted stock units will vest on December 1, 2022, 25% will vest on December 1, 2023, 25% will vest on December 1, 2024 and the remaining 2% will vest on December 1, 2025.

F12 · derivative.expiration_date: 48% of these restricted stock units will vest on December 1, 2022, 25% will vest on December 1, 2023, 25% will vest on December 1, 2024 and the remaining 2% will vest on December 1, 2025.

SEC source: 0000899243-22-036383 · doc4.xml · derivative · entry 12

Justice Angela · CIK 0001732986 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 62,586 shares

Expires 2030-12-09

F13 · price: On November 17, 2022, the issuer cancelled, pursuant to the issuer's offer to exchange eligible options for new restricted stock units program, a stock option granted to the reporting person on December 10, 2020. In exchange for such stock option, the reporting person received restricted stock units in the amount of 11,380.

F10 · derivative.exercise_date: This cancelled option vested 25% on January 1, 2022 and the remaining 75% vests in 36 substantially equal monthly installments thereafter.

SEC source: 0000899243-22-036383 · doc4.xml · derivative · entry 11

Justice Angela · CIK 0001732986 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 803

Underlying: Common Stock · 803 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents a right to receive one share of the issuer's common stock at the time of vesting for no consideration.

F11 · price: On November 17, 2022, the issuer cancelled, pursuant to the issuer's offer to exchange eligible options for new restricted stock units program, a stock option granted to the reporting person on December 10, 2020. In exchange for such stock option, the reporting person received restricted stock units in the amount of 803.

F12 · derivative.exercise_date: 48% of these restricted stock units will vest on December 1, 2022, 25% will vest on December 1, 2023, 25% will vest on December 1, 2024 and the remaining 2% will vest on December 1, 2025.

F12 · derivative.expiration_date: 48% of these restricted stock units will vest on December 1, 2022, 25% will vest on December 1, 2023, 25% will vest on December 1, 2024 and the remaining 2% will vest on December 1, 2025.

SEC source: 0000899243-22-036383 · doc4.xml · derivative · entry 10

Justice Angela · CIK 0001732986 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,414 shares

Expires 2030-12-09

F11 · price: On November 17, 2022, the issuer cancelled, pursuant to the issuer's offer to exchange eligible options for new restricted stock units program, a stock option granted to the reporting person on December 10, 2020. In exchange for such stock option, the reporting person received restricted stock units in the amount of 803.

F10 · derivative.exercise_date: This cancelled option vested 25% on January 1, 2022 and the remaining 75% vests in 36 substantially equal monthly installments thereafter.

SEC source: 0000899243-22-036383 · doc4.xml · derivative · entry 9

Justice Angela · CIK 0001732986 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,626

Underlying: Common Stock · 2,626 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents a right to receive one share of the issuer's common stock at the time of vesting for no consideration.

F9 · price: On November 17, 2022, the issuer cancelled, pursuant to the issuer's offer to exchange eligible options for new restricted stock units program, a stock option granted to the reporting person on December 19, 2019. In exchange for such stock option, the reporting person received restricted stock units in the amount of 2,626.

F8 · derivative.exercise_date: 73% of these restricted stock units will vest on December 1, 2022, 25% will vest on December 1, 2023 and the remaining 2% will vest on December 1, 2024.

F8 · derivative.expiration_date: 73% of these restricted stock units will vest on December 1, 2022, 25% will vest on December 1, 2023 and the remaining 2% will vest on December 1, 2024.

SEC source: 0000899243-22-036383 · doc4.xml · derivative · entry 8

Justice Angela · CIK 0001732986 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,876 shares

Expires 2029-12-18

F9 · price: On November 17, 2022, the issuer cancelled, pursuant to the issuer's offer to exchange eligible options for new restricted stock units program, a stock option granted to the reporting person on December 19, 2019. In exchange for such stock option, the reporting person received restricted stock units in the amount of 2,626.

F6 · derivative.exercise_date: This cancelled option vested 25% on January 1, 2021 and the remaining 75% vests in 36 substantially equal monthly installments thereafter.

SEC source: 0000899243-22-036383 · doc4.xml · derivative · entry 7

Justice Angela · CIK 0001732986 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,264

Underlying: Common Stock · 1,264 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents a right to receive one share of the issuer's common stock at the time of vesting for no consideration.

F7 · price: On November 17, 2022, the issuer canceled, pursuant to the issuer's offer to exchange eligible options for new restricted stock units program, a stock option granted to the reporting person on December 19, 2019. In exchange for such stock option, the reporting person received restricted stock units in the amount of 1,264.

F8 · derivative.exercise_date: 73% of these restricted stock units will vest on December 1, 2022, 25% will vest on December 1, 2023 and the remaining 2% will vest on December 1, 2024.

F8 · derivative.expiration_date: 73% of these restricted stock units will vest on December 1, 2022, 25% will vest on December 1, 2023 and the remaining 2% will vest on December 1, 2024.

SEC source: 0000899243-22-036383 · doc4.xml · derivative · entry 6

Justice Angela · CIK 0001732986 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,791 shares

Expires 2029-12-18

F7 · price: On November 17, 2022, the issuer canceled, pursuant to the issuer's offer to exchange eligible options for new restricted stock units program, a stock option granted to the reporting person on December 19, 2019. In exchange for such stock option, the reporting person received restricted stock units in the amount of 1,264.

F6 · derivative.exercise_date: This cancelled option vested 25% on January 1, 2021 and the remaining 75% vests in 36 substantially equal monthly installments thereafter.

SEC source: 0000899243-22-036383 · doc4.xml · derivative · entry 5

Justice Angela · CIK 0001732986 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,950

Underlying: Common Stock · 58,950 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents a right to receive one share of the issuer's common stock at the time of vesting for no consideration.

F5 · price: On November 17, 2022, the issuer canceled, pursuant to the issuer's offer to exchange eligible options for new restricted stock units program, a stock option granted to the reporting person on October 10, 2019. In exchange for such stock option, the reporting person received restricted stock units in the amount of 58,950.

F4 · derivative.exercise_date: 79% of these restricted stock units will vest on December 1, 2022 and the remaining 21% will vest on December 1, 2023.

F4 · derivative.expiration_date: 79% of these restricted stock units will vest on December 1, 2022 and the remaining 21% will vest on December 1, 2023.

SEC source: 0000899243-22-036383 · doc4.xml · derivative · entry 4

Justice Angela · CIK 0001732986 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 176,850 shares

Expires 2029-10-11

F5 · price: On November 17, 2022, the issuer canceled, pursuant to the issuer's offer to exchange eligible options for new restricted stock units program, a stock option granted to the reporting person on October 10, 2019. In exchange for such stock option, the reporting person received restricted stock units in the amount of 58,950.

F1 · derivative.exercise_date: This cancelled option vested 25% on October 10, 2020 with the remaining 75% vesting in 36 substantially equal monthly installments thereafter.

SEC source: 0000899243-22-036383 · doc4.xml · derivative · entry 3

Justice Angela · CIK 0001732986 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,466

Underlying: Common Stock · 5,466 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents a right to receive one share of the issuer's common stock at the time of vesting for no consideration.

F2 · price: On November 17, 2022, the issuer canceled, pursuant to the issuer's offer to exchange eligible options for new restricted stock units program, a stock option granted to the reporting person on October 10, 2019. In exchange for such stock option, the reporting person received restricted stock units in the amount of 5,466.

F4 · derivative.exercise_date: 79% of these restricted stock units will vest on December 1, 2022 and the remaining 21% will vest on December 1, 2023.

F4 · derivative.expiration_date: 79% of these restricted stock units will vest on December 1, 2022 and the remaining 21% will vest on December 1, 2023.

SEC source: 0000899243-22-036383 · doc4.xml · derivative · entry 2

Justice Angela · CIK 0001732986 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,398 shares

Expires 2029-10-11

F2 · price: On November 17, 2022, the issuer canceled, pursuant to the issuer's offer to exchange eligible options for new restricted stock units program, a stock option granted to the reporting person on October 10, 2019. In exchange for such stock option, the reporting person received restricted stock units in the amount of 5,466.

F1 · derivative.exercise_date: This cancelled option vested 25% on October 10, 2020 with the remaining 75% vesting in 36 substantially equal monthly installments thereafter.

SEC source: 0001209191-22-020023 · doc4.xml · nonDerivative · entry 2

Justice Angela · CIK 0001732986 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,693

F1 · kind: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the issuer's 2018 Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of September 1, 2021 through February 28, 2022. This transaction is exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on February 28, 2022.

SEC source: 0001209191-21-069048 · doc4.xml · derivative · entry 3

Justice Angela · CIK 0001732986 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,500

Underlying: Common Stock · 76,500 shares

Expires 2031-12-08

F3 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 1, 2023, with the remainder vesting in thirty-six (36) equal monthly installments thereafter

SEC source: 0001209191-21-069048 · doc4.xml · nonDerivative · entry 2

Justice Angela · CIK 0001732986 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,457

F1 · kind: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the issuer's 2018 Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of March 1, 2021 through August 31, 2021. This transaction is exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on August 31, 2021.

SEC source: 0001209191-21-024608 · doc4.xml · derivative · entry 2

Justice Angela · CIK 0001732986 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 193,248

Underlying: Common Stock · 6,752 shares

Expires 2029-10-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The Reporting Person was granted an option to purchase 200,000 shares on October 10, 2019. 25% of this option vested and became exercisable on October 10, 2020, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.

SEC source: 0001209191-21-024608 · doc4.xml · nonDerivative · entry 1

Justice Angela · CIK 0001732986 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,078

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-21-010268 · doc4.xml · nonDerivative · entry 1

Justice Angela · CIK 0001732986 · Chief People Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 326

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the issuer's 2018 Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of September 1, 2020 through February 28, 2021. This transaction is exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on September 1, 2020.

SEC source: 0000899243-20-033474 · doc4.xml · derivative · entry 1

Justice Angela · CIK 0001732986 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,000

Underlying: Common Stock · 67,000 shares

Expires 2030-12-09

F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 1, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.

SEC source: 0001638833-19-000057 · wf-form4_156218494056345.xml · derivative · entry 3

Justice Angela · CIK 0001732986 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,889

Underlying: Common Stock · 103,111 shares

Expires not disclosed

F3 · shares: Unvested options forfeited upon termination.

F3 · derivative.exercise_date: Unvested options forfeited upon termination.

F3 · derivative.expiration_date: Unvested options forfeited upon termination.

SEC source: 0001638833-19-000057 · wf-form4_156218494056345.xml · nonDerivative · entry 2

Justice Angela · CIK 0001732986 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,154

F2 · shares: Unvested shares forfeited upon termination.

SEC source: 0001638833-19-000057 · wf-form4_156218494056345.xml · nonDerivative · entry 1

Justice Angela · CIK 0001732986 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,602

F1 · shares: Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting on July 1, 2019 of restricted stock.

SEC source: 0001638833-19-000019 · wf-form4_155302300158781.xml · nonDerivative · entry 3

Justice Angela · CIK 0001732986 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,466

F3 · shares: Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting on March 16, 2019 of restricted stock.

SEC source: 0001638833-19-000019 · wf-form4_155302300158781.xml · derivative · entry 4

Justice Angela · CIK 0001732986 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,000

Underlying: Common Stock · 116,000 shares

Expires 2029-03-15

F4 · derivative.exercise_date: One-third (1/3) of the options will vest in three equal installments on each of December 31, 2020, December 31, 2021, and December 31, 2022, generally contingent upon continued employment through each applicable vesting date (the "time condition"). One-third (1/3) of the options will vest based on satisfaction of the time condition and the achievement of a closing price per share of the Issuer's Common Stock of $25.00. The remaining one-third (1/3) of the options will vest based on satisfaction of the time condition and the achievement of a closing price per share of the Issuer's Common Stock of $35.00.

SEC source: 0001638833-19-000019 · wf-form4_155302300158781.xml · nonDerivative · entry 2

Justice Angela · CIK 0001732986 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,043

F2 · shares: Shares will vest in three equal annual installments of each of the first three anniversaries of March 15, 2019.

SEC source: 0001638833-19-000019 · wf-form4_155302300158781.xml · nonDerivative · entry 1

Justice Angela · CIK 0001732986 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,660

F1 · shares: Shares issued based on 2018 performance under performance stock unit awards granted to the Reporting Person on March 16, 2018. Shares will vest in two equal annual installments on each of the first two anniversaries of December 31, 2018.

SEC source: 0000904454-18-000243 · edgar.xml · nonDerivative · entry 1

Justice Angela · CIK 0001732986 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,830